

Aspects of serum and sputum antibody in chronic airways obstruction

C. W. CLARKE

Department of Bacteriology, Cardiothoracic Institute, Fulham Road, London SW3 6HP

Clarke, C. W. (1976). *Thorax*, 31, 702–707. **Aspects of serum and sputum antibody in chronic airways obstruction.** Immunoglobulin levels and precipitating antibody against a range of microbial antigens were measured in simultaneously collected serum and sputum samples from patients with chronic bronchitis (11), cystic fibrosis (9), bronchiectasis (9), and asthma (4). Sputum was prepared by dialysis and high-speed centrifugation methods.

Results showed that it was possible to detect precipitating antibody in the sputum, and the rate was increased when both methods were used. A discrepancy was noted between the detection rate in the sputum and serum. This, combined with the lack of correlation between sputum and serum immunoglobulins, lack of relationship between bronchial inflammation and sputum immunoglobulins, and the lack of IgM in the sputum suggested that the antibody and immunoglobulin were locally produced.

Sputum IgA (7S) in patients with chronic bronchitis was significantly lower ($P < 0.05$) than that found in patients with cystic fibrosis and bronchiectasis. Significant differences ($P < 0.05$) were also noted in serum IgG levels between patients with chronic bronchitis, bronchiectasis, and cystic fibrosis while serum IgM levels in patients with chronic bronchitis were significantly lower ($P < 0.05$) when compared to serum levels in patients with cystic fibrosis.

The presence of precipitating antibody in the sputum raises the possibility that type III reactions may be important in the pathogenesis of these conditions.

The mechanisms of pathogenicity of microbial organisms in the respiratory tract, as in other areas of the body, are poorly understood (Smith, 1972). Additionally, the extensive resident flora of the upper respiratory tract (Austrian, 1968) makes difficult the assessment of the significance of organisms isolated from the sputum. Studies of precipitating antibody in the serum of patients with chronic airways obstruction against certain bacterial antigens (May, 1975) have attempted to deal with this problem although the significance of these results (Tager and Speizer, 1975) is still not clear. Previous studies have shown that it is possible to detect immunoglobulins and antibody against microbial and other antigens in sputum (Biberfeld and Sterner, 1971; Medici and Buergi, 1971; Falk, Okinaka, and Siskind, 1972; Gump *et al.*, 1973; Ryley and Brogan, 1973; Shore, Potter, and Stuart-Harris, 1973; Deuschl and Johansson, 1974; Wallwork *et al.*, 1974; Warren and Tse, 1974; Brogan *et al.*, 1975; Clarke, 1975).

Bacterial infection of the lower respiratory tract is known to be frequent in chronic bronchial disorders such as chronic bronchitis, bronchiectasis, and cystic fibrosis whereas the normal bronchial tree is known to be sterile (Brumfitt, Willoughby, and Bromley, 1957; Lees and McNaught, 1959). This suggests that there may be an abnormality of respiratory defences in patients with these conditions.

The aim of the present study was to determine the immunoglobulin content and antibody response of patients with chronic airways obstruction against microbial antigens as measured in simultaneously collected sputum and serum samples in order to determine if these measurements would provide insight into the mechanisms of bacterial pathogenicity in these conditions.

METHOD

Patients with confirmed diagnoses of chronic bronchitis (11), cystic fibrosis (9), bronchiectasis

(9), and asthma (4) were selected for study. Submission of sputum to the Bacteriology Department served as entry to the study. Patients with sufficient sputum available on the morning of the study were then selected. No account was taken of the patient's age, sex, severity of disease, smoking history or treatment. The sputum obtained from each patient represented approximately 18 hours overnight collection. Bloodstained sputum was not used. A minimum of 20 ml was required for analysis. This proved to be a limiting factor in the case of asthmatic patients as very few of the patients available produced this volume of sputum. Sputum purulence was classified as proposed by May (1972a). Blood was collected at the same time as the sputum collection. Serum was stored with sodium azide at 4°C until tested.

PREPARATION OF SPUTUM FOR EXAMINATION For immunological analysis sputum was prepared in two ways:

1. Four millilitres of sputum were subjected to high-speed centrifugation in a Measuring and Scientific Equipment (MSE) Superspeed 65 centrifuge at 54 500 revolutions per minute (rpm) (120 000 g) at a temperature of 4–6°C for 30 minutes (Ryley and Brogan, 1968). The supernatant sol phase was stored with sodium azide at 4°C until tested. The sediment or gel phase was homogenized with Pancreatin (BDH Biochemicals, Poole) from pig pancreas and cultured (May, 1972b).

2. The remainder of the sample was then diluted with three times its volume of distilled water and dialysed against distilled water, with frequent changes, at 4°C for 72 hours. Following this the dialysate was centrifuged at 10 000 rpm at 4°C for 30 minutes in an MSE 18 centrifuge. The supernatant was collected and freeze dried. This material was then stored at 4°C until tested (Longbottom, personal communication, 1973).

Immunoglobulin estimations were performed by radial diffusion using commercially available plates (Behringwerke, AG). Low level plates were used for the estimation of sputum IgA (7S) and IgM. Precipitating antibody was detected using gel immunodiffusion techniques, as recommended by May (1972c). Freeze-dried sputum preparations were reconstituted at 60 mg/ml in normal saline; preparations prepared by high-speed centrifugation were used without modification. Reconstituted sputum could not be used for quantitative estimation of sputum immunoglobulin. Bacterial and fungal antigens used in

this study were as described previously (Clarke, 1975). Antigen concentrations are listed in Table I.

TABLE I
ANTIGEN CONCENTRATIONS USED IN IMMUNODIFFUSION STUDIES ON SPUTUM AND SERUM

Antigen	Abbreviation	Concentration (mg/ml)
<i>H. influenzae</i> cytoplasmic	H(1·5)	20 10
<i>H. influenzae</i> specific cytoplasmic	H(1·2)	10 1
<i>H. influenzae</i> cell wall	H CW	10
<i>Ps. aeruginosa</i> cytoplasmic	P(1·5)	10
<i>Ps. aeruginosa</i> cell wall	PCW	1
<i>K. pneumoniae</i> cytoplasmic	K(1·5)	10
<i>Staph. aureus</i>	Ø	10
<i>Strep. pneumoniae</i>	Pn.	2
<i>A. fumigatus</i>	A. fum.	30 10

The chi square test (Colton, 1974) was used to analyse the relationship between the presence of precipitating antibody and sputum purulence. The Mann-Whitney U statistic (Meredith, 1967) was used to compare sputum and serum immunoglobulin levels in the various disease groups while the coefficient of correlation (Colton, 1974) was calculated for the relationship of serum to sputum immunoglobulins. These levels were first ranked in descending order of magnitude, and the coefficient was calculated from these. Means were calculated for immunoglobulin levels in the different disease groups. However, in some groups, values were truncated and in these the medians were calculated.

RESULTS

The overall results of the precipitating antibody studies are summarized in Table II, which lists the number of times a particular organism was isolated from the sputum, the number of patients with precipitating antibody in the sputum against the antigens used (which represents the total for both methods), and the number of patients with precipitating antibody in the serum against these same antigens. In Table III the number of patients with precipitating antibody against the different antigens is compared according to the method used. It can be seen that a combination of methods is required to give a greater detection rate.

It can also be seen from Table II that there is a discrepancy between the number of patients with precipitating antibody in the serum to a particular antigen and the number of patients with precipi-

TABLE II

FOR EACH DISEASE STATE, THE NUMBER OF ISOLATIONS OF A PARTICULAR ORGANISM FROM THE SPUTUM, THE INCIDENCE OF PRECIPITATING ANTIBODY DETECTED IN THE SPUTUM (COMBINATION OF METHODS) AND THE SERUM AGAINST ANTIGENS DERIVED FROM THAT ORGANISM ARE SUMMARIZED

Organism with respective antigens derived from it	Chronic Bronchitis (11)			Cystic Fibrosis (9)			Bronchiectasis (9)			Asthma (4)		
	Sputum Culture	Sputum Precipitins	Serum Precipitins	Sputum Culture	Sputum Precipitins	Serum Precipitins	Sputum Culture	Sputum Precipitins	Serum Precipitins	Sputum Culture	Sputum Precipitins	Serum Precipitins
<i>H. influenzae</i> Isolation H (1·2) HCW	3	4 3	11 5	0	4 0	6 8	3	6 0	7 8	2	1 0	1 0
<i>Ps. aeruginosa</i> Isolation P (1·5) PCW	5	1 3	2 1	8	2 7	5 6	2	0 2	2 3	2	0 0	0 1
<i>K. pneumoniae</i> Isolation K (1·5)	0	0	1	0	1	3	0	0	1	0	0	1
<i>Staph. aureus</i> Isolation Antigen	0	0	2	0	0	1	0	0	4	0	0	0
<i>Strep. pneumoniae</i> Isolation Antigen	0	0	1	0	0	0	1	0	1	0	0	0
<i>A. fumigatus</i> Isolation Antigen	0	0	1	0	0	3	0	1	1	0	0	0

TABLE III

NUMBER OF PATIENTS WITH PRECIPITATING ANTIBODY TO MICROBIAL ORGANISMS ACCORDING TO METHOD USED

Disease State and Patient Number	Dialysis Method	High-speed Centrifugation Method	Combination of Methods
Chronic bronchitis (11)	5	5	7
Cystic fibrosis (9)	6	9	9
Bronchiectasis (9)	5	5	7
Asthma (4)	0	1	1

tating antibody detected against the same antigen in the sputum. This discrepancy is also noted between sputum and serum antibody. This latter situation is summarized in Table IV.

Table V summarizes immunoglobulin estimations made on sputum and matching serum samples in the disease groups. It is appreciated that, by estimating 7S IgA only, the total amount of IgA present in the sputum is underestimated.

TABLE IV

PRECIPITATING ANTIBODY AGAINST BACTERIAL ANTIGENS IN THE SPUTUM AND SERUM FOR THOSE PATIENTS IN WHOM THE SPUTUM RESULT DIFFERED FROM THAT IN THE SERUM

Sputum Result		Serum Result		
PCW	HCW	HCW	H(1·2)	P(1·5)
PCW		H(1·2)	K(1·5)	Pn
H(1·2)		K(1·5)		
PCW		HCW	H(1·2)	K(1·5) Ø
PCW	H(1·2)	H(1·2)		
H(1·2)		HCW	Ø	

Comparison of the various sputum and serum immunoglobulin values was carried out between the various disease states. A number of differences were found to be statistically significant ($P < 0.05$). Sputum IgA (7S) in patients with chronic bronchitis was significantly lower than that found in patients with cystic fibrosis and bronchiectasis. Serum IgG in patients with chronic bronchitis was significantly lower than the IgG level found in patients with cystic fibrosis and bronchiectasis. The serum IgG was significantly lower in patients with bronchiectasis than in patients with cystic fibrosis. Serum IgM levels in patients with chronic bronchitis were significantly lower than in patients with cystic fibrosis.

An analysis was made of sputum and serum immunoglobulins in patients with chronic bronchitis and bronchiectasis having 25% (MP+) and 75% (MP+++) or more pus in the sputum. The only significant relationship found was that the serum IgG was higher in patients with 25% pus in their sputum compared to those with 75% or more pus in patients with chronic bronchitis. The number of patients (14) with MP+ sputum who had precipitating antibody in the sputum (8) was compared to those patients (19) with MP+++ sputum and precipitating antibody in the sputum (16). No significant difference was found. The coefficients of correlation were calculated to see if serum immunoglobulin could be correlated to the level of sputum immunoglobulins. No significant correlation was found.

TABLE V
SPUTUM AND SERUM IMMUNOGLOBULIN LEVELS EXPRESSED AS GRAMS/LITRE

Disease and Patient Number	IgG		IgA(7S)		IgM	
	Sputum	Serum	Sputum	Serum	Sputum	Serum
Chronic bronchitis (11)						
Range	<0.7-6.3	5.9-15.01	<0.1-0.94	1.26->4.5	0-0.45	0.83-1.71
Mean	3.35*	11.35	0.68*	3.07*	0.12	1.17
SD		3.52			0.203	0.308
Cystic Fibrosis (9)						
Range	<0.7-9.3	14.13-31.8	0.48-1.1	1.45-7	0-0.54	1.56-8.38
Mean	5.8*	19.87*	0.86	3.24*	0.19	2.15*
SD			0.203		0.23	
Bronchiectasis (9)						
Range	2.3-7.3	10.83->20	0.5-1.1	1.64->4.5	0-0.6	0.66-3.26
Mean	5.38	14.55*	0.85	2.74*	0.21	1.84
SD	1.94		0.2		0.25	0.82
Asthma (4)						
Range	<0.7-7.2	6.55-12.05	0.74-0.94	1.84-2.12	0	1.08-1.86
Mean	3.4*	8.59	0.85	2.03	0	1.55
SD		2.4	0.096	0.13		0.34

SD = standard deviation; * = median. Mean unable to be calculated because of truncated values. Normal serum values from this laboratory (g/litre): IgG 5-15; IgA 1.25-4.5; IgM 0.5-1.7.

DISCUSSION

A problem with any study on sputum is to decide what contribution is made to the results by serum transudation, and formulae have been derived to estimate this (Deuschl and Johansson, 1974). Results presented in this study suggest that serum transudation may not be such an important factor as far as immunoglobulins are concerned. This is supported by the observations that precipitins present in serum are not detected in the sputum in many instances, precipitating antibody may be detected in the sputum but not in the serum, the degree of bronchial inflammation as judged by sputum purulence does not appear to have any relationship to sputum immunoglobulin levels or the presence of precipitating antibody, IgM is rarely present in the sputum, and the level of immunoglobulin in the serum bears no relationship to the level of immunoglobulin present in the sputum.

This study confirms the finding in a previous study that precipitating antibody may be detected against bacterial and fungal antigens in the sputum (Clarke, 1975). Detection of precipitating antibody against bacterial antigens in the serum of patients with these diseases has led some investigators to attach pathogenic significance to certain organisms that may be isolated from the sputum in these diseases (May, 1975). It is often difficult in an individual patient to assess the pathogenic significance of an organism isolated from a sample of sputum at a given time. A search for sputum precipitins may facilitate this assessment. Support for this idea comes from a study of precipitating antibody to other inhaled

antigens, viz, chicken antigens. It was shown by bronchial challenge testing that the antigens against which sputum precipitating antibody was directed had more relevance clinically than those against which serum antibody was directed (Warren and Tse, 1974). A study of cystic fibrosis patients also demonstrated higher titres of sputum than of serum precipitins to certain antigens (Wallwork *et al.*, 1974).

The detection of precipitating antibody to bacterial antigen in sputum raises the possibility that type III or Arthus reactions could play a part in these conditions, as has been demonstrated for *Aspergillus fumigatus* (Katz and Kniker, 1973). In support of this was the demonstration of extensive deposits of immunoglobulins and complement immune complexes in the respiratory tract of patients with cystic fibrosis (McFarlane *et al.*, 1975).

It is apparent from this study that the antigens used in the detection of precipitating antibody are of importance. Certainly with *Pseudomonas aeruginosa* and, to a lesser extent, *Haemophilus influenzae* it is the cell wall antigen that appears to have more relevance. This may be one reason why precipitating antibody was not detected against *Ps. aeruginosa* in a study of the sputum of patients with cystic fibrosis (Wallwork *et al.*, 1974).

As the method of preparation of the cell wall antigen is the same as that for the preparation of endotoxin and the cell wall and cytoplasmic antigens of *H. influenzae* have been shown to contain endotoxin (Branefors-Helander, 1973; Van Der Zwan, Orie, and De Vries, 1975) the detection of precipitating antibody to these antigens

suggests that endotoxin is being released into the bronchial tree. This may contribute to the pathological processes by activation of the alternate pathway for complement (Götze and Müller-Eberhard, 1971), recruitment (Wittels *et al.*, 1974) and pulmonary intravascular sequestration of leucocytes (Kilburn *et al.*, 1974), increasing vascular permeability, allowing inhaled antigens access to the circulation (Parish, 1972), releasing and causing *de novo* synthesis of histamine directly (Szetivanyi, 1971) with subsequent mucous hypersecretion and mucosal oedema (Brocklehurst, 1970), and increased bronchial reactivity in a similar manner to that produced by the endotoxin of *Bordetella pertussis* in experimental animals (Reed, 1968).

The immunoglobulin results are of interest. The low IgA (7S) in the sputum of patients with chronic bronchitis compared to the other disease states raises the possibility that its production in chronic bronchitis may be abnormal, as suggested elsewhere (Medici and Buerger, 1971). The lack of IgM in the sputum is supported by other studies (Falk *et al.*, 1972; Gump *et al.*, 1973) while the presence of IgG and IgA (7S) in the sputum of patients with bronchiectasis and cystic fibrosis gives further support to the concept that a defect of local immunoglobulin production is probably not the cause of the chronic infection seen in these conditions (Martinez-Tello, Braun, and Blane, 1968). The significant differences in the sputum and serum immunoglobulins in the different disease states reported here may reflect a difference in the severity of the infection or a difference in the capacity to react to infection.

I should like to thank Dr. I. Daz and Miss G. Leballeur, of the Department of Experimental Pathology, Cardiothoracic Institute, for arranging high-speed centrifugation; Mr. S. Nagarajah, of Brompton Hospital, for carrying out immunoglobulin estimations; Mr. D. E. Roberts, Chief Technician in the Department, for technical help; and the Board of Governors, National Heart and Chest Hospitals, Brompton Hospital for financial support.

REFERENCES

- Austrian, R. (1968). The bacterial flora of the respiratory tract. Some knowns and unknowns. *Yale Journal of Biology and Medicine*, **40**, 400.
- Biberfeld, G. and Sterner, G. (1971). Antibodies in bronchial secretions following natural infections with *Mycoplasma pneumoniae*. *Acta Pathologica et Microbiologica Scandinavica Section B*, **79**, 599.
- Branefors-Helander, P. (1973). Serological studies of *Haemophilus influenzae*. III. The endotoxic effect of various antigen preparations and the relation between this effect and demonstrable precipitogens. *International Archives of Allergy and Applied Immunology*, **44**, 585.
- Brocklehurst, W. E. (1970). Pharmacological factors mediating bronchial obstruction. In *Bronchitis III (Proceedings of the Third International Symposium on Bronchitis at Groningen, The Netherlands, September 1969)*, edited by N. G. M. Orie and R. van Der Lende, p. 279, Royal Vangorcum, Assen.
- Brogan, T. D., Ryley, H. C., Neale, L., and Yassa, J. (1975). Soluble proteins of bronchopulmonary secretions from patients with cystic fibrosis, asthma, and bronchitis. *Thorax*, **30**, 72.
- Brumfit, W., Willoughby, M. L. N., and Bromley, L. L. (1957). An evaluation of sputum examination in chronic bronchitis. *Lancet*, **2**, 1306.
- Clarke, C. W. (1975). Precipitating antibody in the sputum in chronic respiratory disease. *Postgraduate Medical Journal*, **51**, 147.
- Colton, T. (1974). *Statistics in Medicine*, p. 174. Little Brown, Boston.
- Deuschl, H. and Johansson, S. G. O. (1974). Immunoglobulins in tracheo-bronchial secretion with special reference to IgE. *Clinical and Experimental Immunology*, **16**, 401.
- Falk, G. A., Okinaka, A. J., and Siskind, G. W. (1972). Immunoglobulins in the bronchial washings of patients with chronic obstructive pulmonary disease. *American Review of Respiratory Diseases*, **105**, 14.
- Götze, O. and Müller-Eberhard, H. J. (1971). The C3-activator system: an alternate pathway of complement activation. *Journal of Experimental Medicine*, **134**, 90S.
- Gump, D. W., Christmas, W. A., Forsyth, B. R., Phillips, C. A., and Stouch, W. H. (1973). Serum and secretory antibodies in patients with chronic bronchitis. *Archives of Internal Medicine*, **133**, 847.
- Katz, R. M. and Kniker, W. T. (1973). Infantile hypersensitivity pneumonitis as a reaction to organic antigens. *New England Journal of Medicine*, **288**, 233.
- Kilburn, K. H., Hudson, A. R., Halprin, G. M., McKenzie, W. N., and Merchant, J. A. (1974). Two patterns for bronchial damage from inhaled materials. *Chest*, **65**, 4, Supplement 61S.
- Lees, A. W. and McNaught, W. (1959). Bacteriology of lower respiratory tract secretions, sputum, and upper-respiratory-tract secretions in 'normal' and chronic bronchitis. *Lancet*, **2**, 1112.
- Longbottom, J. L. (1973). Personal communication.
- McFarlane, H., Holzel, A., Brenchley, P., Allan, J. D., Wallwork J. C., Singer, B. E., and Worsley, B. (1975). Immune complexes in cystic fibrosis. *British Medical Journal*, **1**, 423.
- Martinez-Tello, F. J., Braun, D. G., and Blanc, W. A. (1968). Immunoglobulin production in bronchial mucosa and bronchial lymph nodes, particularly in cystic fibrosis of the pancreas. *Journal of Immunology*, **101**, 989.

- May, J. R. (1972). *The Chemotherapy of Chronic Bronchitis and Allied Disorders*, 2nd edition, (a) p. 4, (b) p. 95, (c) p. 99. The English Universities Press Ltd., London.
- May, J. R. (1975). The flora of the respiratory tract in chronic disease. *Postgraduate Medical Journal*, **51**, 144.
- Medici, T. C. and Buergi, H. (1971). The role of immunoglobulin A in endogenous bronchial defense mechanisms in chronic bronchitis. *American Review of Respiratory Diseases*, **103**, 784.
- Meredith, W. M. (1967). *Basic Mathematical and Statistical Tables for Psychology and Education*, p. 288. McGraw-Hill, New York.
- Parish, W. E. (1972). Host damage resulting from hypersensitivity to bacteria. *Symposia of the Society for General Microbiology*, **22**, 157.
- Reed, C. E. (1968). Pertussis sensitization as an animal model for the abnormal bronchial sensitivity of asthma. *Yale Journal of Biology and Medicine*, **40**, 507.
- Ryley, H. C. and Brogan, T. D. (1968). Variation in the composition of sputum in chronic chest diseases. *British Journal of Experimental Pathology*, **49**, 625.
- Ryley, H. C. and Brogan, T. D. (1973). Quantitative immunoelectrophoretic analysis of the plasma proteins in the sol phase of sputum from patients with chronic bronchitis. *Journal of Clinical Pathology*, **26**, 852.
- Shore, S. L., Potter, C. W., and Stuart-Harris, C. H. (1973). Antibody response to inactivated influenza vaccine given by different routes in patients with chronic bronchopulmonary disease. *Thorax*, **28**, 721.
- Smith, H. (1972). The little-known determinants of microbial pathogenicity. *Symposia of the Society for General Microbiology*, **22**, 1.
- Szetivanyi, I. (1971). Effect of bacterial products and adrenergic blocking agents on allergic reactions. In *Immunological Diseases*, 2nd edition, edited by M. Samter, Vol. 1, p. 356. Little, Brown, Boston.
- Tager, I. and Speizer, F. E. (1975). Role of infection in chronic bronchitis. *New England Journal of Medicine*, **292**, 563.
- Van Der Zwan, J. C., Orie, N. G. M., and De Vries, K. (1975). Biphasic reaction after inhalation of *Haemophilus influenzae* in patients with chronic nonspecific lung disease. *Clinical Allergy*, **5**, 225.
- Wallwork, J. C., Brenchley, P., McCarthy, J., Allan, J. D., Moss, D., Milford Ward, A., Holzel, A., Williams, R. F., and McFarlane, H. (1974). Some aspects of immunity in patients with cystic fibrosis. *Clinical and Experimental Immunology*, **18**, 303.
- Warren, C. P. W. and Tse, K. S. (1974). Extrinsic allergic alveolitis owing to hypersensitivity to chickens—significance of sputum precipitins. *American Review of Respiratory Diseases*, **109**, 672.
- Wittels, E. H., Coalson, J. J., Welch, M. H., and Guenter, C. A. (1974). Pulmonary intravascular leucocyte sequestration: a potential mechanism of lung injury. *American Review of Respiratory Diseases*, **109**, 502.

Requests for reprints to: Dr. C. W. Clarke, Royal Brisbane Hospital, Brisbane, Queensland 4029, Australia.